Combination therapy with BRAF and MEK inhibitors for melanoma: Latest evidence and place in therapy

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 1, 2016, Pages 48-56

  Eroglu, Zeynep ^a   Ribas, Antoni ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF inhibitors; MEK inhibitors; Melanoma

Indexed keywords

B RAF KINASE INHIBITOR; BINIMETINIB; COBIMETINIB; DABRAFENIB; ENCORAFENIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; TRAMETINIB; VEMURAFENIB;

BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 84951778317     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015616934     Document Type: Review

References (49)

1. Algazi A. Othus M. Daud A. Mehnert J. Lao C. Kudchadkar R. et al. (2015) SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma. J Clin Oncol 33: TPS9093.
2. Ascierto P. Minor D. Ribas A. Lebbe C. O'Hagan A. Arya N. et al. (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31: 3205–3211.
3. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
4. Daud A. Ribas A. Robert C. Hodi F. Wolchok J. Joshua A. et al. (2015 a) Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33: 9005.
5. Daud A. Weber J. Sosman J. Kim K. Gonzalez R. Hamid O. et al. (2015 b) Updated overall survival (OS) results for BRF113220, a phase I–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V 600 metastatic melanoma (MM). J Clin Oncol 33: 9036.
6. Davies H. Bignell G. Cox C. Stephens P. Edkins S. Clegg S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
7. Davies M. Martins K. Sessa T. Swann S. (2014) Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: a GSK-sponsored trial. J Clin Oncol 32: TPS9106.
8. Dummer R. Goldinger S. Turtschi C. Eggmann N. Michielin O. Mitchell L. et al. (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50: 611–621.
9. Flaherty K. Infante J. Daud A. Gonzalez R. Kefford R. Sosman J. et al. (2012 a) Combined BRAF and MEK inhibition in melanoma with BRAF V 600 mutations. N Eng J Med 367: 1694–1703.
10. Flaherty K. Robert C. Hersey P. Nathan P. Garbe C. Milhem M. et al. (2012 b) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Eng J Med 367: 107–114.
11. Frederick D. Piris A. Cogdill A. Cooper Z. Lezcano C. Ferrone C. et al. (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19: 1225–1231.
12. Hauschild A. Grob J. Demidov L. Jouary T. Gutzmer R. Millward M. et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358–365.
13. Hodi F. O'Day S. Mcdermott D. Weber R. Sosman J. Haanen J. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
14. Hodi F. Sznol M. Kluger H. McDermott D. Carvajal R. Lawrence D. et al. (2014) Long-term survival of ipilimumab-naive patients with advanced melanoma treated with nivolumab in a phase I trial. J Clin Oncol 32: 9002.
15. Hu-Lieskovan S. Mok S. Homet Moreno B. Tsoi J. Robert L. Goedert L. et al. (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 7: 279ra41.
16. Johnson D. Flaherty K. Weber J. Infante J. Kim K. Kefford R. et al. (2014) Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 32: 3697–3704.
17. Kim D. Barcena E. Mehta U. Rohlfs M. Kumar A. Penas-Prado M. et al. (2015) Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer 15: 400.
18. Kim K. Kefford R. Pavlick A. Infante J. Ribas A. Sosman J. et al. (2013) Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31: 482–489.
19. Larkin J. Ascierto P. Dreno B. Atkinson V. Liszkay G. Maio M. et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371: 1867–1876.
20. Larkin J. Yan Y. Mcarthur G. Ascierto P. Liszkay G. Maio M. et al. (2015) Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 33: 9006.
21. Long G. Fung C. Menzies A. Pupo G. Carlino M. Hyman J. et al. (2014 a) Increased MAPK reactivation in early resistance to dabrafenib / trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 5: 5694.
22. Long G. Stroyakovskiy D. Gogas H. Levchenko E. de Braud F. Larkin J. et al. (2014 b) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Eng J Med 371: 1877–1888.
23. Long G. Stroyakovskiy D. Gogas H. Levchenko E. de Braud F. Larkin J. et al. (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val 600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386: 444–451.
24. Long G. Trefzer U. Davies M. Kefford R. Ascierto P. Chapman P. et al. (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087–1095.
25. Mateus C. Routier E. Roy S. Thomas M. Boussemart L. Girault I. Chaput-Gras N. et al. (2014) Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. J Clin Oncol 32: TPS9114.
26. Menzies A. Wilmott J. Drummond M. Lo S. Lyle M. Chan M. et al. (2015) Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121: 3826–3835.
27. Mittapalli R. Vaidhyanathan S. Dudek A. Elmquist W. (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344: 655–664.
28. Moriceau G. Hugo W. Hong A. Shi H. Kong X. Yu C. et al. (2015) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF / MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27: 240–256.
29. Paraiso K. Haarberg H. Wood E. Rebecca V. Chen Y. Xiang Y. et al. (2012) The HSP 90 inhibitor XL 888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18: 2502–2514.
30. Pavlick A. Ribas A. Gonzalez R. Hamid O. Gajewski T. Daud A. et al. (2015) Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. J Clin Oncol 33: 9020.
31. Puzanov I. (2015) Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) J Transl Med 13(Suppl. 1): K8.
32. Ribas A. Butler M. Lutzky J. Lawrence D. Robert C. Miller W. et al. (2015) Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and / or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol 33: 3003.
33. Ribas A. Gonzalez R. Pavlick A. Hamid O. Gajewski T. Daud A. et al. (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 15: 954–965.
34. Ribas A. Kefford R. Marshall M. Punt C. Haanen J. Marmol M. et al. (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616–622.
35. Rizos H. Menzies A. Pupo G. Carlino M. Fung C. Hyman J. et al. (2014) BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 20: 1965–1977.
36. Robert C. Karaszewska B. Schachter J. Rutkowski P. Mackiewicz A. Stroiakovski D. et al. (2015 a) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Eng J Med 372: 30–39.
37. Robert C. Schachter J. Long G. Arance A. Grob J. Mortier L. et al. (2015 b) The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 73: 6106–6110.
38. Sakji-Dupré L. Le Rhun E. Templier C. Desmedt E. Blanchet B. Mortier L. (2015) Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma. Melanoma Research 25: 302–305.
39. Schadendorf D. Hodi F. Robert C. Weber J. Margolin K. Hamid O. et al. (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. doi:10.1200/JCO.2014.56.2736.
40. Schäfer N. Scheffler B. Stuplich M. Schaub C. Kebir S. Rehkämper C. et al. (2013) Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 31: e173–e174.
41. Shi H. Hugo W. Kong X. Hong A. Koya R. Moriceau G. et al. (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4: 80–93.
42. Sosman J. Kim K. Schuchter L. Gonzalez R. Pavlick A. Weber J. et al. (2012) Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib. N Eng J Med 366: 707–714.
43. Su F. Viros A. Milagre C. Trunzer K. Bollag G. Spleiss O. et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207–215.
44. Sullivan R. Weber J. Patel S. Dummer R. Miller W. Cosgrove D. et al. (2015) A phase Ib / II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol 33: 9007.
45. Thakur M. Stuart D. (2013) The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 73: 6106–6110.
46. Wagle N. Emery C. Berger M. Davis M. Sawyer A. Pochanard P. et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085–3096.
47. Wargo J. Cooper Z. Flaherty K. (2014) Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov 4: 1377–1386.
48. Wilmott J. Long G. Howle J. Haydu L. Sharma R. Thompson J. et al. (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18: 1386–1394.
49. Yee M. Lin Y. Gorantla V. Butterfield L. Kluger H. Chapman P. et al. (2015) Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). J Clin Oncol 33: TPS9088.